Chronic hepatitis C virus infection in 2013--quo vadis?

Rev Med Chir Soc Med Nat Iasi. 2013 Jan-Mar;117(1):7-10.
No abstract available

Publication types

  • Editorial
  • Multicenter Study

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Hepacivirus / drug effects*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / pathology
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon-alpha / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • Prevalence
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use*
  • Romania / epidemiology
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • peginterferon alfa-2a